Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Nuvalent Inc (NUVL) – Nuvalent Inc Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

NUVL trades at $102.54, down 1.92% on the day, with a bullish technical signal from moving averages but a neutral oscillator reading. The company is a clinical-stage biopharmaceutical firm with two key oncology assets advancing through FDA review. Financials show significant losses with a net income of -$425.38 million in 2025, but a strong cash position of $1.37 billion provides runway through 2029. Recent developments include NDA submissions for neladalkib and zidesamtinib, with a PDUFA date for the latter set for September 18, 2026.
The investment case hinges on successful FDA approvals and commercialization of its pipeline, with a consensus price target of $134.00 implying over 30% upside. Key risks include clinical trial outcomes, regulatory hurdles, and the company's pre-revenue status amid ongoing cash burn. Wall Street sentiment is strongly bullish with 14 buy ratings and no holds or sells.
Read full analysis

Key Stats

  • Market Cap
    $8.10B
  • Sector
    Technology
  • 3M Drawdown
    -9.7%
  • Enterprise Value
    $6.82B
  • Dividend Yield
    -
  • Typical Hold Time
    7 days
$105.15
52W Low: $71
15 May 2025
52W High: $111.99
22 Jan 2026

Nuvalent Inc (NUVL) is currently valued at a market capitalization of $8.10B, with an enterprise value of $6.82B. Over the past 52 weeks, Nuvalent Inc has traded between a low of $71 and a high of $111.99, highlighting its annual price range. Over the past three months, Nuvalent Inc has recorded a drawdown of -9.7%, reflecting recent price volatility. On average, investors hold Nuvalent Inc for approximately 7 days, indicating typical investor behavior on the platform.

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.


Technical Indicators
|
|
|
Overall Summary
Bearish (4)Neutral (8)Bullish (15)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $8.10B
  • Sector
    Technology
  • 3M Drawdown
    -9.7%
  • Enterprise Value
    $6.82B
  • Dividend Yield
    -
  • Typical Hold Time
    7 days
$105.15
52W Low: $71
15 May 2025
52W High: $111.99
22 Jan 2026

Nuvalent Inc (NUVL) is currently valued at a market capitalization of $8.10B, with an enterprise value of $6.82B. Over the past 52 weeks, Nuvalent Inc has traded between a low of $71 and a high of $111.99, highlighting its annual price range. Over the past three months, Nuvalent Inc has recorded a drawdown of -9.7%, reflecting recent price volatility. On average, investors hold Nuvalent Inc for approximately 7 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!